Recent Updates
Recently added Catalysts
CING Positive Sentiment Score: 70/100

Cingulate to Present at 13th Annual LD Micro Invitational

Thursday, May 25, 2023 2 min read
Key Takeaway: Cingulate Inc. (NASDAQ: CING) announced its participation in the 13th Annual LD Micro Invitational taking place from June 6th-8th, 2023, in Los Angeles. The company's CEO, Shane J. Schaffer, will present an overview on June 6th at 9:30 a.m. PST. Cingulate is advancing its lead candidate, CTx-1301, a once-daily treatment for ADHD, while also exploring additional applications of its Precision Timed Release technology for other conditions, such as anxiety.

Market Sentiment Analysis

POSITIVE FACTORS

  • Cingulate's participation in a significant investment event presents growth opportunities.
  • The company is actively developing a Phase 3 treatment for ADHD, addressing a substantial market.
  • Cingulate is exploring additional therapeutic indications like anxiety, indicating potential pipeline expansion.

Full Press Release Details

KANSAS CITY, Kan., May 25, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced it will participate in the 13th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel, Los Angeles, California, on June 6th-8th, 2023. The event is expected to feature 150+ companies, presenting in half-hour increments, as well as private one-on-one meetings.
Cingulate Chairman & CEO Shane J. Schaffer is scheduled to present a company overview on June 6th at 9:30 a.m. PST. A webcast of the presentation will be available on the investors section of Cingulate’s corporate site at www.cingulate.com.
Cingulate’s lead Phase 3 candidate, CTx-1301, is a novel, investigational treatment being developed as a true, once-daily stimulant medication for attention deficit/hyperactivity disorder (ADHD). In addition to the Company’s initial focus on the $22bn ADHD market, Cingulate is identifying other indications, such as anxiety, where it’s PTR™ technology may be effectively utilized.
To arrange a meeting with Cingulate, please contact your LD Micro representative, or Cingulate investor relations at mkreps@darrowir.com.
Cingulate Inc. (NASDAQ: CING), is a clinical-stage biopharmaceutical company utilizing its proprietary PTR™ drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of neurological disorders, Cingulate is identifying and evaluating additional therapeutic areas where PTR™ technology may be employed to develop future product candidates, including to treat anxiety disorders. Cingulate is headquartered in Kansas City. For more information visit Cingulate.com.
Vice President, Investor & Public Relations, Cingulate
TDalton@cingulate.com
Darrow Associates Investor Relations

Tags

Precision Timed Release

Frequently Asked Questions

What is Cingulate Inc. known for?

Cingulate Inc. focuses on developing next-generation pharmaceutical products using its PTR™ technology.

What is CTx-1301?

CTx-1301 is Cingulate's lead Phase 3 candidate for treating ADHD as a once-daily stimulant.

When will Cingulate present at LD Micro Invitational?

Cingulate will present on June 6th at 9:30 a.m. PST during the LD Micro Invitational.

How can I contact Cingulate for a meeting?

You can arrange a meeting by contacting your LD Micro representative or Cingulate Investor Relations.

Where is Cingulate Inc. headquartered?

Cingulate Inc. is headquartered in Kansas City, Kansas.

Tags: CING Viatris Investor Conferences Healthcare Cingulate ADHD precision timed release biopharmaceuticals
Last updated: May 25, 2023